about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

An­oth­er sci­en­tist pleads guilty for his role in a scheme to sell GSK's trade se­crets in Chi­na

7 years ago
People
China

Can­cer Re­search UK launch­es new Lon­don Cen­tre, in­fus­ing £14M in­to bio­ther­a­peu­tics work from lead­ing in­sti­tutes

7 years ago
R&D
Pharma

Hua Med­i­cine reaps $110.5M, ad­just­ing ex­pec­ta­tions for Hong Kong IPO

7 years ago
News Briefing

Top sci­en­tist Thor Voigt vaults to CMO role at Boehringer In­gel­heim; Cel­gene's Scott Smith tapped as pres­i­dent at ...

7 years ago
Peer Review

Su­per­nus bags ear­ly-stage CNS drug for $15M up­front in re­newed epilep­sy R&D ef­forts

7 years ago
Deals

Phar­ma com­pa­nies out­per­form in­sti­tu­tions in Eu­ro­pean clin­i­cal tri­al re­port­ing amid prob­lem­at­ic over­all trends — ...

7 years ago
Pharma

Scout­ing ear­ly-stage on­col­o­gy plays, bio­phar­ma vets Detlev Bin­iszkiewicz, Scott Chap­pel make VC de­but at MPM

7 years ago
People
Financing

Vi­tal Ther­a­pies evis­cer­at­ed as PhI­II dis­as­ter forces it to dis­card sole as­set

7 years ago
R&D

GSK-backed sci­en­tif­ic team at UCSF says they found the im­mor­tal­i­ty switch in can­cer cells — and know how to turn it ...

7 years ago
Discovery

Chi­nese phar­ma pow­er­house Han­soh joins fledg­ling biotechs in the Hong Kong IPO line

7 years ago
Financing
China

Ovid ex­ec Yaron Wer­ber cross­es back to Cowen; Saqib Is­lam pro­mot­ed to Spring­Work­s' first CEO slot

7 years ago
Peer Review

New in­vestors pool $120M to bankroll Al­lo­gene's off-the-shelf CAR-T pipeline in dri­ve to stay in the lead

7 years ago
Financing

Atara brings an­oth­er ex­pe­ri­enced in­ves­ti­ga­tor on­to its off-the-shelf CAR-T quest in lat­est col­lab­o­ra­tion

7 years ago
R&D
Discovery

A new CAR-T is cred­it­ed with a 'sur­pris­ing' im­pact in tiny study of ad­vanced liv­er can­cer — rais­ing hopes on sol­id ...

7 years ago
R&D

Li­cens­ing As­traZeneca castoff, Bio­haven preps PhI­II ef­fort in new neu­rode­gen­er­a­tive in­di­ca­tion

7 years ago
R&D
Pharma

FDA waves Loxo through for sec­ond 'break­through' in tis­sue-ag­nos­tic can­cer ther­a­py

7 years ago
Pharma

Phase­Bio rais­es $34M to test or­phan dis­ease strat­e­gy — fo­cus­ing first on As­traZeneca drug

7 years ago
Financing

Sanofi reaps first fruit of Abl­ynx buy­out with a Eu­ro­pean OK for its lead rare dis­ease drug

7 years ago
Pharma

Il­lus­tri­ous Cam­bridge sci­en­tists join forces with $129M fund to bet on long plays in biotech

7 years ago
Financing

Ed­i­tas CMO to ex­it as CRISPR tech gears up; Roche di­ag­nos­tics di­vi­sion CEO Roland Diggel­mann is out

7 years ago
Peer Review

Qim­ing, Hill­house bet on Ja­co­bio's nascent pipeline of first-in-class drug hope­fuls in $55M round

7 years ago
Financing
China

Bay­er gets green light to sell long-act­ing he­mo­phil­ia A ther­a­py as Roche mus­cles in with Hem­li­bra

7 years ago
Pharma

Am­gen vet Lau­ra Hamill takes com­mer­cial reins at Gilead amid ex­ec­u­tive shake­up

7 years ago
People

A faster treat­ment for tu­ber­cu­lo­sis? TB Al­liance launch­es piv­otal tri­al for four-drug reg­i­men

7 years ago
R&D
Discovery
First page Previous page 111112113114115116117 Next page Last page
A service from the Financial Times